Related Experiment Video

Updated: Jun 19, 2026

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii
09:17

A Robust Pneumonia Model in Immunocompetent Rodents to Evaluate Antibacterial Efficacy against S. pneumoniae, H. influenzae, K. pneumoniae, P. aeruginosa or A. baumannii

Published on: January 2, 2017

A population pharmacokinetic model for pegylated-asparaginase in children

Georg Hempel1, Hans-Joachim Müller, Claudia Lanvers-Kaminsky

  • 1Institut für Pharmazeutische und Medizinische Chemie - Klinische Pharmazie-, Westfälische Wilhelms-Universität Münster, Germany. georg.hempel@uni-muenster.de

British Journal of Haematology
|October 14, 2009
PubMed

Insights

A new pharmacokinetic model predicts pegylated (PEG)-asparaginase activity over time in children with acute lymphoblastic leukaemia. This model aids in optimizing PEG-asparaginase dosing regimens for improved treatment outcomes.

Area of Science:

  • Pharmacology
  • Oncology
  • Pediatrics

Background:

  • Acute lymphoblastic leukaemia (ALL) treatment often involves asparaginase.
  • Pegylated (PEG)-asparaginase offers prolonged activity but requires careful dosing.
  • Understanding PEG-asparaginase pharmacokinetics is crucial for effective treatment.

Purpose of the Study:

  • To develop a pharmacokinetic model for PEG-asparaginase activity in children with ALL.
  • To describe the activity-time course across various PEG-asparaginase doses.
  • To provide a tool for optimizing future dosing strategies.

Main Methods:

  • Analysis of 1221 serum activity measurements from 168 children in ALL-BFM studies.
  • Utilized nonlinear mixed effects modeling (NONMEM) to analyze data.
  • Tested various linear and nonlinear pharmacokinetic models.

Main Results:

  • A one-compartmental model with time-dependent clearance best described PEG-asparaginase activity.
  • Key parameters: Volume of distribution (V) and initial clearance (Cl(i)).
  • Significant interindividual and interoccasion variability observed; some patients showed high clearance, possibly due to antibodies.

Conclusions:

  • The developed model accurately predicts PEG-asparaginase activity over time at different doses.
  • This model can inform the development of novel and optimized PEG-asparaginase dosing regimens.
  • Further investigation into antibody development and its impact on clearance is warranted.

More Related Videos

Preparing a 68Ga-labeled Arginine Glycine Aspartate (RGD)-peptide for Angiogenesis07:48

Preparing a 68Ga-labeled Arginine Glycine Aspartate (RGD)-peptide for Angiogenesis

Published on: January 7, 2019

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood11:36

A RAPID Method for Blood Processing to Increase the Yield of Plasma Peptide Levels in Human Blood

Published on: April 28, 2016

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure (CHF).
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...